<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782897</url>
  </required_header>
  <id_info>
    <org_study_id>2016ncx01</org_study_id>
    <nct_id>NCT02782897</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin for Acute Intracranial Hemorrhage</brief_title>
  <official_title>A Pilot Study of Safety and Efficacy of Intravenous Immunoglobulin Therapy in Patients With Acute Intracranial Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to investigate whether intravenous immunoglobulin is safe and effective
      in alleviating perihematomal edema and neurologic deficits in patients with intracranial
      hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of two groups: IVIg group and control group. Thirty patients will be
      recruited into IVIg group. Thirty Patients who are matched for age, gender, National
      Institutes of Health Stroke Scale scores, hematomal volumes, and locations of hematomas, will
      be selected into control group. Patients in control group just receive standard management,
      while those in IVIg group will receive standard management plus intravenous immunoglobulin
      therapy. The outcome assessor is blinded to the group assignments.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of the patients with mRS of 3 or more</measure>
    <time_frame>90 days after the onset of ICH</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in hematoma volume</measure>
    <time_frame>At baseline, 7 days, 14 days and 30 days after the onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral edema volume</measure>
    <time_frame>At baseline, 7 days, 14 days and 30 days after the onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days after the onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS score</measure>
    <time_frame>30 days, 90 days after the onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mBI score</measure>
    <time_frame>30 days, 90 days after the onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe adverse events</measure>
    <time_frame>30 days, 90 days after the onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the levels of blood CRP, MMP-9, IL-6, TNF-alpha, and C3</measure>
    <time_frame>At baseline, 5 days after the first administration of immunoglobulin</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intracranial Hemorrhage, Hypertensive</condition>
  <arm_group>
    <arm_group_label>IVIg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunoglobulin Therapy</intervention_name>
    <description>Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.</description>
    <arm_group_label>IVIg group</arm_group_label>
    <other_name>Human Immunoglobulin (pH4) for Intravenous Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard management</intervention_name>
    <description>Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.</description>
    <arm_group_label>IVIg group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Conventional treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The first-ever primary supratentorial intracerebral basal ganglia hemorrhage 5-30ml.

          2. 18-80 years old.

          3. No longer than 72 hours from the acute ICH to medication.

          4. Glasgow Coma Score ≥8.

        Exclusion Criteria:

          1. Occurrences of secondary intracerebral hemorrhage.

          2. Significant past history of disability, modified Rankin Scale（mRS）≥1.

          3. Currently taking antitumor drugs, immunosuppressive drugs, or immunomodulatory
             therapy.

          4. Patients with pregnancy, Severe infection, severe heart dysfunction or renal and
             hepatic injuries.

          5. Patients with contraindications for immunoglobulin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shabei Xu, Doctor</last_name>
    <phone>86-13554178768</phone>
    <email>xushabei@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiang Luo, Doctor</last_name>
    <phone>86-15172507950</phone>
    <email>flydottjh@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Tongji Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shabei Xu, Doctor</last_name>
      <phone>86-13554178768</phone>
      <email>xushabei@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiang Luo, Doctor</last_name>
      <phone>86-15172507950</phone>
      <email>flydottjh@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Wei Wang</investigator_full_name>
    <investigator_title>Tongji Hospital, Huazhong University of Science and Technology</investigator_title>
  </responsible_party>
  <keyword>intravenous immunoglobulin</keyword>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>perihematomal edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Hypertensive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

